New Pharmaceuticals market report from GlobalData: "Iressa (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022"

Boston, MA -- (SBWire) -- 10/10/2013 --Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment landscape into smaller niche patient populations. Over the forecast period, this trend will continue with the launch of multiple new drugs in several new drug classes to address the high unmet need among NSCLC patients, and provide new treatment options for previously underserved populations. Launch of premium-priced drug candidates combined with increasing incident cases of the disease will be major drivers of growth in the major markets.

View Full Report Details and Table of Contents

AstraZeneca's once-daily oral EGFR TKI, Iressa is indicated for first-line use as a monotherapy for advanced-stage, EGFR-positive patients. It is approved for reimbursement for conditional first-line treatment in the UK (NICE, 2010). However, due to its failure to provide superior OS compared with standard chemotherapy in all patients, regardless of EGFR mutation, Iressa's marketing status was revoked in the US by the FDA in 2005 (Iressa package insert, 2013). Iressa is marketed by AstraZeneca in the EU and Japan.

Scope

- Overview of NSCLC, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Iressa including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Iressa for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for NSCLC
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Iressa performance
- Obtain sales forecast for Iressa from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Non-Small Cell Lung Cancer - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Non-Small Cell Lung Cancer - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Non-Small Cell Lung Cancer - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Non-Small Cell Lung Cancer - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Non-Small Cell Lung Cancer - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Non-Small Cell Lung Cancer - India Drug Forecast and Market Analysis to 2022
- PharmaPoint: Non-Small Cell Lung Cancer - China Drug Forecast and Market Analysis to 2022
- PharmaPoint: Non-Small Cell Lung Cancer - US Drug Forecast and Market Analysis to 2022
- EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022